Evidence map›Paper›PMID 20658749›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2010

Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.

Fiona C Lampe, Daniel A Duprez, Lewis H Kuller, Russell Tracy, James Otvos, Erik Stroes, David A Cooper, Jennifer Hoy, Nick I Paton, Nina Friis-Møller and 4 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Acute coronary syndromes in patients with HIV.Coronary artery disease · 2017
    Review
  4. Review
  5. Article
  6. Article
  7. HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.Mediterranean journal of hematology and infectious diseases · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 5 countries.

Fiona C LampeResearch Department of Infection and Population Health, University College London, London, United Kingdom. f.lampe@pcps.ucl.ac.uk
Daniel A Duprez
Lewis H Kuller
Russell Tracy
James Otvos
Erik Stroes
David A Cooper
Jennifer Hoy
Nick I Paton
Nina Friis-Møller
Jacquie Neuhaus
Angelike P Liappis
Andrew N Phillips
INSIGHT SMART Study Group
National Centre for Clinical Research on Emerging Drugs · AUUniversity College London · GBUniversity of Minnesota · USAcademic Medical Center · NLMedical Research Council · GBMonash University · AUUniversity of Copenhagen · DKUniversity of Pittsburgh · USUniversity of Vermont · USVeterans Health Administration · US

Funding

COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDSU01AI046362 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI GORDIN, FRED M · 2000 to 2006
$75.9M
TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ONU01AI042170 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 1997 to 2006
$23.2M
Medical Research Council MC_U122886352NIAID NIH HHS U01 AI042170NIAID NIH HHS U01AI042170NIAID NIH HHS U01 AI046362NIAID NIH HHS U01AI46362
6 · The paper itself

Abstract

backgroundThe effect of interruption of antiretroviral therapy (ART) on lipoprotein particle subclasses has not been studied. We examined short-term changes in lipids and lipoprotein particles among 332 HIV-infected individuals randomized to interrupt or continue ART in the "Strategies for Management of Antiretroviral Therapy" trial.

methodsLipids and lipoprotein particles measured by nuclear magnetic resonance spectroscopy were compared between randomized groups at month 1; associations with inflammatory and coagulation markers (high sensitivity C-reactive protein; interleukin 6; amyloid A; amyloid P; D-dimer; prothrombin fragment 1 + 2) were assessed.

resultsCompared with continuation of ART, treatment interruption resulted in substantial declines in total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride, at month 1 but had little net effect on total/HDL cholesterol ratio [baseline-adjusted mean difference [95% confidence interval (CI)] interruption versus continuation arms: -0.10 (-0.59 to 0.38); P = 0.67]. ART interruption resulted in declines in total, large, and medium very low density lipoprotein (VLDL) particle concentrations (VLDL-p) and total and medium HDL-p. However, there was no change in small HDL-p [baseline-adjusted percentage difference between arms: -4.6% (-13.1%, +5.1% ); P = 0.35], small LDL-p [-5.0% (-16.9%, +8.6%); P = 0.45], or other LDL-p subclasses. Changes in lipid parameters on ART interruption did not differ according to baseline ART class (protease inhibitor versus non-nucleoside reverse transcriptase inhibitor) but were negatively associated both with changes in HIV viral load and with changes in inflammatory and coagulation markers, particularly D-dimer.

conclusionsThese results suggest that ART interruption does not favorably influence overall lipid profile: there was little net effect on total/HDL cholesterol ratio, and no change in small LDL-p or small HDL-p, the lipoprotein particle subclasses most consistently linked to coronary risk. Short-term declines in lipid parameters after ART interruption were not associated with class of ART and may be linked to increases in viral replication, inflammation and coagulation.

Indexed as

AdultAnti-HIV AgentsBiomarkersDrug Administration ScheduleFemaleHIV InfectionsHumansLipidsLipoproteinsMaleMiddle AgedTime FactorsAnti-HIV AgentsBiomarkersLipidsLipoproteins

Identifiers

PMID20658749
PMCPMC3117147
OpenAlexW2168402817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.